Skip to content


Kymriah (tisagenlecleucel) is a cell pharmaceutical. Tisagenlecleucel was first approved as Kymriah on 2018-08-22. It has been approved in Europe to treat large b-cell lymphoma diffuse and precursor b-cell lymphoblastic leukemia-lymphoma.
Trade Name Kymriah
Common Name Tisagenlecleucel
Indication large b-cell lymphoma diffuse, precursor b-cell lymphoblastic leukemia-lymphoma
Drug Class
Get full access now